Table 2 Subgroup analysis assessing the effect of omega-3 FAs supplementation on metabolic parameters in CKD patients
Variable | Sub-grouped by | No. of arms | effect size (SMD) | 95% CI | I2 (%) | P for heterogeneity | |
|---|---|---|---|---|---|---|---|
TC | Duration | > 10 weeks | 8 | −0.31 | − 0.66, 0.03 | 64.1 | 0.007 |
≤10 weeks | 3 | −0.14 | − 0.41, 0.13 | 00.0 | 0.540 | ||
omega-3 FAs dosage | ≤ 2000 mg/day | 5 | −0.61 | −1.07, − 0.14a | 58.9 | 0.045 | |
>  2000 mg/day | 6 | −0.04 | −0.23, − 0.15 | 00.0 | 0.961 | ||
TG | Duration | > 10 weeks | 8 | −0.36 | −0.63, − 0.10a | 38.3 | 0.125 |
≤10 weeks | 3 | 0.03 | −0.23, 0.29 | 00.0 | 0.692 | ||
omega-3 FAs dosage | ≤ 2000 mg/day | 5 | −0.36 | − 0.74, 0.02 | 40.5 | 0.151 | |
>  2000 mg/day | 7 | −0.12 | −0.35, 0.10 | 23.7 | 0.249 | ||
HDL | Duration | > 10 weeks | 7 | −0.49 | −0.90, − 0.09a | 71.8 | 0.002 |
≤10 weeks | 3 | 0.83 | −0.32, 1.97 | 92.6 | 0.000 | ||
omega-3 FAs dosage | ≤ 2000 mg/day | 5 | 0.04 | −0.97, 1.06 | 93.0 | 0.000 | |
>  2000 mg/day | 5 | −0.18 | − 0.53, 0.17 | 55.2 | 0.063 | ||
LDL | Duration | > 10 weeks | 6 | −0.06 | −0.27, 0.16 | 00.0 | 0.513 |
≤10 weeks | 3 | −0.17 | −0.44, 0.10 | 00.0 | 0.948 | ||
omega-3 FAs dosage | ≤ 2000 mg/day | 4 | −0.10 | −0.40, 1.20 | 22.0 | 0.278 | |
>  2000 mg/day | 5 | −0.13 | −0.35, 0.10 | 00.0 | 0.937 | ||